Posts

Fibrostenotic Crohn’s Disease (FSCD) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Fibrostenotic Crohn’s Disease (FSCD) Emerging Therapy and TPP Insights Thelansis’s “Fibrostenotic Crohn’s Disease (FSCD) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Fibrostenotic Crohn’s Disease (FSCD) Overview Fibrostenotic Crohn’s disease is a complications-driven phenotypic subtype of Crohn’s disease where chronic transmural inflammation triggers irreversible extracellular matrix deposition and fixed mechanical strictures. Patients present with postprandial cramping, distension, and vomiting, though structural narrowings can develop silently over years. Cross-sectional CT or MR enterography is the diagnostic standard, though contemporary protocols increasingly integrate point-of-care intestinal ultrasound to track bowel wall thic...
Post a Comment
Read more

Congenital Adrenal Hyperplasia (CAH) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Congenital Adrenal Hyperplasia (CAH) Emerging Therapy and TPP Insights Thelansis’s “Congenital Adrenal Hyperplasia (CAH) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Congenital Adrenal Hyperplasia (CAH) Overview Congenital adrenal hyperplasia (CAH) is a group of autosomal recessive adrenal steroidogenesis disorders, with 21-hydroxylase deficiency caused by CYP21A2 mutations accounting for over 90% of cases, disrupting cortisol and aldosterone biosynthesis while redirecting steroid precursors toward androgen excess. Disease severity spans classic salt-wasting CAH presenting neonatally with adrenal crisis, hyponatremia, hyperkalemia, and virilization, through simple virilizing and non-classic forms manifesting with premature adrenarche...
Post a Comment
Read more

Ankylosing Spondylitis (AS) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Ankylosing Spondylitis (AS) Emerging Therapy and TPP Insights Thelansis’s “Ankylosing Spondylitis (AS) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Ankylosing Spondylitis (AS) Overview Ankylosing Spondylitis is a chronic, immune-mediated spondyloarthropathy strongly associated with the HLA-B27 gene, characterized by enthesitis, sacroiliitis, and progressive spinal fusion driven by severe TNF and IL-17 axis dysregulation. It manifests as insidious, inflammatory back pain and persistent morning stiffness that improves with physical activity. Extramusculoskeletal signs include acute anterior uveitis, extensive plaque psoriasis, and subclinical inflammatory bowel disease. Diagnosis combines clinical presentation, elevated ...
Post a Comment
Read more

Aneurysmal Subarachnoid Hemorrhage (aSAH) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Aneurysmal Subarachnoid Hemorrhage (aSAH) Emerging Therapy and TPP Insights Thelansis’s “Aneurysmal Subarachnoid Hemorrhage (aSAH) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Aneurysmal Subarachnoid Hemorrhage (aSAH) Overview Aneurysmal subarachnoid hemorrhage (aSAH) is a catastrophic neurological emergency caused by intracranial aneurysm rupture, discharging arterial blood into the subarachnoid space and driving acute intracranial hypertension. Presentation is defined by a sudden thunderclap headache, meningism, photophobia, and rapid altered consciousness. Non-contrast cranial CT provides definitive initial screening, backed by lumbar puncture for xanthochromia if neuroimaging is negative. Severity is graded clinica...
Post a Comment
Read more

Acute Kidney Injury (AKI) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Acute Kidney Injury (AKI) Emerging Therapy and TPP Insights Thelansis’s “Acute Kidney Injury (AKI) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Acute Kidney Injury (AKI) Overview Acute kidney injury (AKI) is a rapid decline in renal function defined by an abrupt reduction in glomerular filtration rate, worsening azotemia, and frequent oliguria. It is classified by KDIGO criteria into three progressive stages based on serum creatinine spikes and urine output drops. Pathophysiology spans prerenal hemodynamic insufficiency (sepsis, volume depletion), intrinsic parenchymal damage (ischemic or nephrotoxic acute tubular necrosis), and postrenal obstructive uropathy. Severe cases manifest with critical fluid overload, metabolic acidosis, an...
Post a Comment
Read more

Acromegaly – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Acromegaly Emerging Therapy and TPP Insights Thelansis’s “Acromegaly Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Acromegaly Overview Acromegaly is an insidious endocrine disorder characterized by progressive somatic overgrowth driven by chronic growth hormone (GH) hypersecretion—typically from a benign pituitary adenoma—and subsequent elevation of insulin-like growth factor 1 (IGF-1). Because its onset is subtle, definitive diagnosis is notoriously delayed by four to ten years. Left unmanaged, patients develop distinctly enlarged, spade-like extremities, facial bone distortions, and systemic morbidities including hypertrophic cardiomyopathy and secondary diabetes mellitus. Transsphenoidal surgical resection remains the definitive fi...
Post a Comment
Read more

Developmental and Epileptic Encephalopathies (DEEs) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Developmental and Epileptic Encephalopathies (DEEs) Emerging Therapy and TPP Insights Thelansis’s “Developmental and Epileptic Encephalopathies (DEEs) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Developmental and Epileptic Encephalopathies (DEEs) Overview Developmental and epileptic encephalopathies (DEEs) are a heterogeneous group of severe, pediatric-onset neurodevelopmental syndromes characterized by drug-resistant epilepsy, developmental stagnation or regression, and cognitive deficits. Unlike classic epilepsies, DEEs damage neurodevelopment through both the underlying genetic or structural etiology and the continuous, disruptive electrographic activity itself. Syndromic archetypes like Dravet, Lennox-Gastaut, and SCN2A/8A mutat...
Post a Comment
Read more